IL107896A - Method for the production of apoliprotein ai-m and an expression vector enabling said production - Google Patents
Method for the production of apoliprotein ai-m and an expression vector enabling said productionInfo
- Publication number
- IL107896A IL107896A IL10789693A IL10789693A IL107896A IL 107896 A IL107896 A IL 107896A IL 10789693 A IL10789693 A IL 10789693A IL 10789693 A IL10789693 A IL 10789693A IL 107896 A IL107896 A IL 107896A
- Authority
- IL
- Israel
- Prior art keywords
- apolipoprotein
- promoter
- apo
- production
- sequence coding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
- C12N15/71—Expression systems using regulatory sequences derived from the trp-operon
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9203753A SE9203753D0 (sv) | 1992-12-11 | 1992-12-11 | Expression system for producing apolipoprotein ai-m |
Publications (2)
Publication Number | Publication Date |
---|---|
IL107896A0 IL107896A0 (en) | 1994-04-12 |
IL107896A true IL107896A (en) | 2004-06-01 |
Family
ID=20388112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL10789693A IL107896A (en) | 1992-12-11 | 1993-12-06 | Method for the production of apoliprotein ai-m and an expression vector enabling said production |
Country Status (22)
Country | Link |
---|---|
US (1) | US5721114A (no) |
EP (1) | EP0677109B1 (no) |
JP (1) | JP3899121B2 (no) |
AT (1) | ATE191930T1 (no) |
AU (1) | AU5663794A (no) |
CA (1) | CA2150928C (no) |
CZ (1) | CZ290865B6 (no) |
DE (1) | DE69328442T2 (no) |
DK (1) | DK0677109T3 (no) |
ES (1) | ES2146646T3 (no) |
FI (1) | FI952847A (no) |
GR (1) | GR3033966T3 (no) |
HU (1) | HU220193B (no) |
IL (1) | IL107896A (no) |
MX (1) | MX9307855A (no) |
NO (1) | NO319497B1 (no) |
PL (1) | PL175955B1 (no) |
PT (1) | PT677109E (no) |
SE (1) | SE9203753D0 (no) |
SK (1) | SK76695A3 (no) |
WO (1) | WO1994013819A1 (no) |
ZA (1) | ZA939266B (no) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9500778D0 (sv) * | 1995-03-03 | 1995-03-03 | Pharmacia Ab | Process for producing a protein |
EP0871713B1 (en) * | 1995-11-09 | 2007-02-14 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | The use of lecithin-cholesterol acyltransferase (lcat) in the treatment of atherosclerosis |
SE9603068D0 (sv) * | 1996-08-23 | 1996-08-23 | Pharmacia & Upjohn Ab | Process for purifying a protein |
SE9603304D0 (sv) | 1996-09-11 | 1996-09-11 | Pharmacia & Upjohn Ab | Process for purifying a compound |
SE9603303D0 (sv) | 1996-09-11 | 1996-09-11 | Pharmacia & Upjohn Ab | Process for purifying a protein |
US6306433B1 (en) | 1997-08-12 | 2001-10-23 | Pharmacia Ab | Method of preparing pharmaceutical compositions |
US6046166A (en) * | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6518412B1 (en) | 1997-09-29 | 2003-02-11 | Jean-Louis Dasseux | Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6037323A (en) | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6004925A (en) | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
CN1297932A (zh) * | 1999-11-30 | 2001-06-06 | 上海博容基因开发有限公司 | 一种新的多肽——人脂蛋白前体蛋白信号肽11和编码这种多肽的多核苷酸 |
US20020064820A1 (en) * | 2000-03-13 | 2002-05-30 | Jean-Michel Dayer | Apo-A-I regulation of T-cell signaling |
CA2428114C (en) * | 2000-11-10 | 2013-07-23 | Proteopharma Aps | Apolipoprotein analogues |
US7217785B2 (en) * | 2001-05-09 | 2007-05-15 | The Regents Of The University Of California | Cysteine-containing peptides having antioxidant properties |
AU2002362612B2 (en) * | 2001-09-28 | 2007-11-15 | Cedars-Sinai Medical Center | Prevention and treatment of restenosis by local administration of drug |
US7470659B2 (en) * | 2001-12-07 | 2008-12-30 | The Regents Of The University Of California | Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM) |
CA2468989A1 (en) * | 2001-12-07 | 2003-06-19 | Daniel M. Schwartz | Treatment for age-related macular degeneration |
US20030229062A1 (en) * | 2001-12-07 | 2003-12-11 | The Regents Of The University Of California | Treatments for age-related macular degeneration (AMD) |
US7223726B2 (en) * | 2002-01-14 | 2007-05-29 | The Regents Of The University Of California | Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same |
US7691965B2 (en) * | 2002-05-08 | 2010-04-06 | The Regents Of The University Of California | Helical synthetic peptides that stimulate cellular cholesterol efflux |
US20100204103A1 (en) * | 2002-05-08 | 2010-08-12 | The Regents Of The University Of California | Helical synthetic peptides that stimulate cellular cholesterol efflux |
MXPA04011227A (es) * | 2002-05-17 | 2005-01-25 | Esperion Therapeutics Inc | Metodos y composiciones para el tratamiento de la reperfusion isquemica. |
MXPA04011312A (es) | 2002-05-17 | 2005-02-14 | Esperion Therapeutics Inc | Metodo para el tratamiento de desordenes dislipidemicos. |
PT2404890T (pt) | 2003-01-23 | 2017-10-23 | Esperion Therapeutics Inc | Compostos de hidroxilo e composições para gestão do colesterol e utilizações relacionadas |
EP1602720B1 (en) * | 2003-03-05 | 2010-11-03 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Process for producing heterologous protein in e. coli |
WO2005097206A2 (en) * | 2004-04-06 | 2005-10-20 | Cedars-Sinai Medical Center | Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein a-i and apolipoprotein a-i milano |
KR100560102B1 (ko) | 2004-06-25 | 2006-03-13 | 한국생명공학연구원 | 프로아포리포단백질 a-ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제 |
CN1320119C (zh) * | 2004-12-09 | 2007-06-06 | 复旦大学 | 人载脂蛋白ApoAⅠ在毕赤氏酵母胞内表达的方法 |
JP5113752B2 (ja) | 2005-08-22 | 2013-01-09 | メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド | Lynキナーゼの活性を調節し、関連する疾患を治療するための方法および製剤 |
KR20080049066A (ko) * | 2005-08-26 | 2008-06-03 | 세레니스 쎄라퓨틱스 홀딩 에스에이 | 유산균에서의 아포지단백질 유전자 생성물의 생성을 위한조성물 및 방법 |
DE102006004871A1 (de) | 2006-02-02 | 2007-08-09 | Wacker Chemie Ag | Mikroorganismenstamm zur Produktion von rekombinanten Proteinen |
US20070254832A1 (en) * | 2006-02-17 | 2007-11-01 | Pressler Milton L | Methods for the treatment of macular degeneration and related eye conditions |
EP2026829B1 (en) | 2006-06-01 | 2013-01-09 | Institut de Cardiologie de Montréal | Compound for use in the treatment of valvular stenosis |
ATE501266T1 (de) | 2006-09-22 | 2011-03-15 | Wacker Chemie Ag | Verfahren zur fermentativen herstellung von antikörpern |
DE102006044841A1 (de) | 2006-09-22 | 2008-04-03 | Wacker Chemie Ag | Signalpeptid zur Produktion von rekombinanten Proteinen |
DE102006050332A1 (de) | 2006-10-25 | 2008-04-30 | Wacker Chemie Ag | DNS-Konstrukt und Verfahren zur fermentativen Herstellung von Fusionsproteinen |
CA3021932C (en) * | 2007-01-31 | 2020-12-15 | Jds Therapeutics, Llc | Use of chromium histidinate for treatment of cardiometabolic disorders |
EP2120581A4 (en) * | 2007-02-20 | 2011-03-16 | Melior Pharmaceuticals I Inc | METHODS OF IDENTIFYING LYN KINASE ACTIVATORS |
PL2134351T3 (pl) | 2007-03-13 | 2017-10-31 | Jds Therapeutics Llc | Sposoby i kompozycje do przedłużonego uwalniania chromu |
WO2009002867A2 (en) | 2007-06-26 | 2008-12-31 | Nutrition 21, Inc. | Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement |
BRPI0813167A2 (pt) * | 2007-07-23 | 2014-12-23 | Melior Discovery Inc | Usos de uma composição e de um agente para modular a atividade e/ou a expressão de irs-1 e/ou akt, e, composto |
JP5600065B2 (ja) * | 2007-10-23 | 2014-10-01 | ザ クリーブランド クリニック ファウンデーション | オキシダント耐性アポリポ蛋白質a−1および類似ペプチド |
US8552184B2 (en) * | 2008-07-03 | 2013-10-08 | Melior Pharmaceuticals I, Inc. | Compounds and methods for treating disorders related to glucose metabolism |
CA3039251C (en) | 2008-11-10 | 2024-01-09 | Arbutus Biopharma Corporation | Novel lipids and compositions for the delivery of therapeutics |
CA2751342C (en) | 2009-01-29 | 2019-05-07 | Alnylam Pharmaceuticals, Inc. | Lipid formulations comprising cationic lipid and a targeting lipid comprising n-acetyl galactosamine for delivery of nucleic acid |
HUE033661T2 (en) | 2009-02-16 | 2017-12-28 | Cerenis Therapeutics Holding Sa | Apolipoprotein A-1 mimetics |
WO2010105209A1 (en) | 2009-03-12 | 2010-09-16 | Alnylam Pharmaceuticals, Inc. | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES |
SG10201911942UA (en) | 2009-05-05 | 2020-02-27 | Muthiah Manoharan | Lipid compositions |
LT2440183T (lt) | 2009-06-10 | 2018-08-10 | Arbutus Biopharma Corporation | Patobulinta lipido kompozicija |
EP2464336A4 (en) | 2009-08-14 | 2013-11-20 | Alnylam Pharmaceuticals Inc | COMPOSITIONS FORMULATED IN LIPIDS AND METHODS OF INHIBITING THE EXPRESSION OF EBOLA VIRUS GENE |
DE102009053566B4 (de) | 2009-11-11 | 2014-08-14 | Südzucker Aktiengesellschaft Mannheim/Ochsenfurt | Mikroorganismen mit gesteigerter Sucrosemutaseaktivität |
CA3044884A1 (en) | 2009-12-07 | 2011-06-16 | Arbutus Biopharma Corporation | Compositions for nucleic acid delivery |
ES2749426T3 (es) | 2009-12-18 | 2020-03-20 | Univ British Columbia | Métodos y composiciones para administración de ácidos nucleicos |
US20130156845A1 (en) | 2010-04-29 | 2013-06-20 | Alnylam Pharmaceuticals, Inc. | Lipid formulated single stranded rna |
WO2011143362A1 (en) | 2010-05-11 | 2011-11-17 | Esperion Therapeutics, Inc. | Dimeric oxidation-resistant apolipoprotein a1 variants |
WO2011150300A1 (en) | 2010-05-28 | 2011-12-01 | Melior Pharmaceuticals I, Inc. | Prevention of pancreatic beta cell degeneration |
CN103096875B (zh) | 2010-06-03 | 2016-08-17 | 阿尔尼拉姆医药品有限公司 | 用于递送活性剂的生物可降解脂质 |
US20130202652A1 (en) | 2010-07-30 | 2013-08-08 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
WO2012016184A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
ES2558751T3 (es) * | 2010-08-30 | 2016-02-08 | F. Hoffmann-La Roche Ag | Alimento alcalino |
US9339513B2 (en) | 2010-11-09 | 2016-05-17 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes |
CA2824526C (en) | 2011-01-11 | 2020-07-07 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
HUE042314T2 (hu) | 2011-02-07 | 2019-06-28 | Cerenis Therapeutics Holding Sa | Lipoprotein komplexek és azok gyártása és alkalmazásai |
MX344925B (es) | 2011-03-01 | 2017-01-11 | N21 Acquisition Holding Llc | Composiciones de insulina y cromo para el tratamiento y prevención de diabetes, hipoglucemia y alteraciones relacionadas. |
EP3456317A1 (en) | 2011-09-27 | 2019-03-20 | Alnylam Pharmaceuticals, Inc. | Di-aliphatic substituted pegylated lipids |
RU2646475C2 (ru) | 2011-12-12 | 2018-03-05 | МЕЛИОР ФАРМАСЬЮТИКАЛЗ Ай, ИНК. | Лечение диабета I и II типа |
WO2014011908A1 (en) | 2012-07-11 | 2014-01-16 | Esperion Therapeutics, Inc. | Apolipoprotein mixtures |
SG11201609084QA (en) | 2014-05-02 | 2016-11-29 | Cerenis Therapeutics Holding Sa | Hdl therapy markers |
US11865121B2 (en) | 2016-02-11 | 2024-01-09 | Nutrition21, LLC | Chromium containing compositions for improving health and fitness |
US10426817B2 (en) * | 2017-01-24 | 2019-10-01 | Macregen, Inc. | Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics |
CN110785170B (zh) | 2017-04-10 | 2023-03-28 | 梅里奥尔医药I公司 | 脂肪细胞的治疗 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8625435D0 (en) * | 1986-10-23 | 1986-11-26 | Erba Farmitalia | Human apolipoprotein ai |
EP0345155B1 (en) * | 1988-05-31 | 1994-08-10 | Mitsubishi Kasei Corporation | Process for producing natural human apolipoprotein e-like proteins |
DE3819463A1 (de) * | 1988-06-08 | 1989-12-14 | Behringwerke Ag | Expressionsvektoren zur herstellung unfusionierter proteine in mikroorganismen |
US5223407A (en) * | 1988-08-31 | 1993-06-29 | Allelix Inc. | Excretion of heterologous proteins from e. coli |
IT1229996B (it) * | 1989-04-20 | 1991-09-20 | Cesare Sirtori | Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine. |
DE68916444T2 (de) * | 1989-10-31 | 1994-11-03 | Schering Corp., Kenilworth, N.J. | Sekretorische e-coli-stämme. |
DE4009268A1 (de) * | 1990-03-22 | 1991-09-26 | Consortium Elektrochem Ind | Sekretion von hirudinderivaten |
SE9103701D0 (sv) * | 1991-12-13 | 1991-12-13 | Kabi Pharmacia Ab | Apolipoprotein |
-
1992
- 1992-12-11 SE SE9203753A patent/SE9203753D0/xx unknown
-
1993
- 1993-12-06 IL IL10789693A patent/IL107896A/en not_active IP Right Cessation
- 1993-12-09 CA CA002150928A patent/CA2150928C/en not_active Expired - Fee Related
- 1993-12-09 CZ CZ19951487A patent/CZ290865B6/cs not_active IP Right Cessation
- 1993-12-09 ES ES94902173T patent/ES2146646T3/es not_active Expired - Lifetime
- 1993-12-09 AU AU56637/94A patent/AU5663794A/en not_active Abandoned
- 1993-12-09 PL PL93309292A patent/PL175955B1/pl not_active IP Right Cessation
- 1993-12-09 WO PCT/SE1993/001061 patent/WO1994013819A1/en active IP Right Grant
- 1993-12-09 US US08/448,606 patent/US5721114A/en not_active Expired - Fee Related
- 1993-12-09 DK DK94902173T patent/DK0677109T3/da active
- 1993-12-09 PT PT94902173T patent/PT677109E/pt unknown
- 1993-12-09 EP EP94902173A patent/EP0677109B1/en not_active Expired - Lifetime
- 1993-12-09 AT AT94902173T patent/ATE191930T1/de not_active IP Right Cessation
- 1993-12-09 JP JP51405994A patent/JP3899121B2/ja not_active Expired - Fee Related
- 1993-12-09 DE DE69328442T patent/DE69328442T2/de not_active Expired - Fee Related
- 1993-12-09 HU HU9501680A patent/HU220193B/hu not_active IP Right Cessation
- 1993-12-09 SK SK766-95A patent/SK76695A3/sk unknown
- 1993-12-10 ZA ZA939266A patent/ZA939266B/xx unknown
- 1993-12-10 MX MX9307855A patent/MX9307855A/es not_active IP Right Cessation
-
1995
- 1995-06-09 NO NO19952297A patent/NO319497B1/no unknown
- 1995-06-09 FI FI952847A patent/FI952847A/fi unknown
-
2000
- 2000-07-17 GR GR20000401651T patent/GR3033966T3/el not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ZA939266B (en) | 1994-08-08 |
IL107896A0 (en) | 1994-04-12 |
FI952847A0 (fi) | 1995-06-09 |
NO952297L (no) | 1995-06-09 |
HU220193B (hu) | 2001-11-28 |
HUT71697A (en) | 1996-01-29 |
NO319497B1 (no) | 2005-08-22 |
DE69328442T2 (de) | 2000-09-07 |
CA2150928C (en) | 2005-02-08 |
PT677109E (pt) | 2000-07-31 |
CZ148795A3 (en) | 1996-01-17 |
ATE191930T1 (de) | 2000-05-15 |
WO1994013819A1 (en) | 1994-06-23 |
HU9501680D0 (en) | 1995-08-28 |
US5721114A (en) | 1998-02-24 |
AU5663794A (en) | 1994-07-04 |
DK0677109T3 (da) | 2000-07-17 |
EP0677109A1 (en) | 1995-10-18 |
DE69328442D1 (de) | 2000-05-25 |
EP0677109B1 (en) | 2000-04-19 |
JP3899121B2 (ja) | 2007-03-28 |
PL175955B1 (pl) | 1999-03-31 |
MX9307855A (es) | 1994-06-30 |
SK76695A3 (en) | 1996-02-07 |
CA2150928A1 (en) | 1994-06-23 |
SE9203753D0 (sv) | 1992-12-11 |
GR3033966T3 (en) | 2000-11-30 |
NO952297D0 (no) | 1995-06-09 |
JPH08506723A (ja) | 1996-07-23 |
ES2146646T3 (es) | 2000-08-16 |
PL309292A1 (en) | 1995-10-02 |
FI952847A (fi) | 1995-06-09 |
CZ290865B6 (cs) | 2002-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5721114A (en) | Expression system for producing apolipoprotein AI-M | |
KR970005928B1 (ko) | 프라세싱 부위에 인접한 음전하를 띤 아미노산을 함유하는 이스트 프라세싱 시스템 | |
US5004686A (en) | Process for producing human epidermal growth factor and analogs thereof | |
Amann et al. | Tightly regulated tac promoter vectors useful for the expression of unfused and fused proteins in Escherichia coli | |
KR100316347B1 (ko) | 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법 | |
US5357044A (en) | Cecropins fusion proteins | |
US5874406A (en) | Synthetic peptide analogs of lung surface protein SP-C | |
JP3730255B2 (ja) | イーストにおいて発現されたn末端に伸長した蛋白質 | |
US5962270A (en) | Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs | |
US5206154A (en) | Method of producing cecropins by microbiological techniques | |
JP5352234B2 (ja) | 特定のエンドプロテアーゼによって塩基性アミノ酸のc末端を用いてポリペプチドをアミド化する方法 | |
Chaudhary et al. | Role of domain II of Pseudomonas exotoxin in the secretion of proteins into the periplasm and medium by Escherichia coli. | |
CZ284204B6 (cs) | Zvyšování sekrece polypeptidů | |
JP2001008697A (ja) | E.コリでの非融合タンパク質の調製方法 | |
EP0946735A1 (en) | N-terminally extended proteins expressed in yeast | |
KR100659671B1 (ko) | 신규한 융합단백질로부터 재조합 인슐린을 제조하는 방법 | |
RU2144957C1 (ru) | РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pPINS07, КОДИРУЮЩАЯ ГИБРИДНЫЙ ПОЛИПЕПТИД, СОДЕРЖАЩИЙ ПРОИНСУЛИН ЧЕЛОВЕКА, И ШТАММ БАКТЕРИЙ Escherichia coli - ПРОДУЦЕНТ ГИБРИДНОГО ПОЛИПЕПТИДА, СОДЕРЖАЩЕГО ПРОИНСУЛИН ЧЕЛОВЕКА | |
CA2241367C (en) | Vector for expression of n-terminally extended proteins in yeast cell | |
AU643194B2 (en) | Recombinant fish hormone proteins | |
AU618011B2 (en) | Preparation of novel protein sweeteners-monellin type | |
KR970000594B1 (ko) | deo 프로모터를 함유하는 형질발현 플라스미드 및 플라스미드를 함유하는 세균숙주 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
MM9K | Patent not in force due to non-payment of renewal fees |